Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02136797 | Completed Phase 2 Results FDA Drug

• 1 other identifier: 14-070
• Study Type: interventional
• Target: 77
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection. A transfusion is the process by which blood from one person is transferred to the blood of another. In this case, the T-cells are made from the blood of donors who are immune to CMV. The T-cells are then grown and taught to attack the CMV virus in a lab.

Conditions

CMV Infection; Persistent CMV Viremia

Keywords

CMVpp65 Specific T-cells; Allogeneic Hematopoietic Stem Cell Transplantation; 14-070

Outcome Measures

Primary Outcomes (1)

• Complete Response

  defined as the clearance of the CMV infection 3-7 weeks following completion of the last cycle of CMV CTLs.

  2 years

Secondary Outcomes (1)

• Number of Participants With SAE's Possibly Related to Study Treatment

  2 years

Study Arms (1)

CMVpp65-CTL T-cells

EXPERIMENTAL

The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 10\^6 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.

Biological: CMVpp65 Specific T-cells

Interventions

CMVpp65 Specific T-cells BIOLOGICAL

CMVpp65-CTL T-cells

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Each patient must satisfy at least one of the following criteria:
• The patient must have a clinically documented condition associated with CMV (e.g. interstitial pneumonia, hepatitis, retinitis, colitis) Or
• The patient must have microbiological evidence of CMV viremia or tissue invasion as attested by viral culture, or detection of levels of CMV DNA in the blood or body fluids consistent with CMV infection.
• Patient must also satisfy at least one of the following criteria:
• The patient's CMV infection is clinically progressing or CMV viremia is persistent or increasing (as evidenced by quantitation of CMV DNA in the blood) despite two weeks induction therapy with antiviral drugs.
• The patient has developed CMV viremia as attested by viral culture, or detection of levels of CMV DNA in blood or body fluids while receiving prophylactic doses of antiviral drugs to prevent CMV infection post transplant.
• The patient is unable to sustain treatment with antiviral drugs due to drug associated toxicities (e.g. myelosuppression \[ANC\< 1000μl/ml without GCSF support\] or nephrotoxicity \[corrected creatinine clearance ≤ 60 ml/min/1.73 m\^2 or serum creatinine \> 2 mg/dl\]) CMV infections are life threatening, and may involve multiple organ systems such as the lungs, liver, gastrointestinal tract, hematopoietic and central nervous systems. Antiviral drugs used for treatment may also compromise renal and hematopoietic function. Therefore, dysfunctions of these organs will not affect eligibility for this protocol.
• Patients must meet the following clinical criteria to receive CMVpp65-CTL infusions
• Stable blood pressure and circulation, not requiring pressor support
• Evidence of adequate cardiac function as demonstrated by EKG and/or echocardiography.
• A life expectancy of at least 3 weeks, even if requiring artificial ventilation.
• There are no age restrictions
• Patient must also satisfy at least one of the following criteria:
• The patient's HCT donor has not been previously infected by or sensitized to CMV (e.g. a cord blood transplant or a marrow or PBSC transplant from a seronegative donor).
• The patient's HCT donor, if seropositive, is either not available or not willing to provide leukocytes for generation of CMV-specific T-cells.

You may not qualify if:

• Patients requiring high doses of glucocorticosteroids (≥ 0.3 mg/kg prednisone or its equivalent)
• Patients who are moribund
• Patients with other conditions not related to CMV infection (e.g. uncontrolled bacterial sepsis or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T-cell infusion.
• Patients who are pregnant

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Cytomegalovirus Infections

Condition Hierarchy (Ancestors)

Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections

Results Point of Contact

• Title: Dr. Kevin Curran, MD
• Organization: Memorial Sloan Kettering Cancer Center

currank@mskcc.org

212-639-5836

Study Officials

• Susan Prockop, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR
• Expanded Access: Yes

Study Record Dates

• First Submitted: May 9, 2014
• First Posted: May 13, 2014
• Study Start: May 8, 2014
• Primary Completion: February 8, 2024
• Study Completion: February 8, 2024
• Last Updated: October 17, 2024
• Results First Posted: October 17, 2024

Record last verified: 2024-07

Locations

US (1)